The cAMP and cAMP Inhibited cGMP 3′,5′ Cyclic Phosphodiesterase 10A pipeline drugs market research report outlays comprehensive information on the cAMP and cAMP Inhibited cGMP 3′,5′ Cyclic Phosphodiesterase 10A targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the cAMP and cAMP Inhibited cGMP 3′,5′ Cyclic Phosphodiesterase 10A pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, and Oncology which include the indications Schizophrenia, Tourette Syndrome, Pancreatic Ductal Adenocarcinoma, and Triple-Negative Breast Cancer (TNBC). It also reviews key players involved in cAMP and cAMP Inhibited cGMP 3′,5′ Cyclic Phosphodiesterase 10A targeted therapeutics development with respective active and dormant or discontinued products.
The cAMP and cAMP Inhibited cGMP 3′,5′ Cyclic Phosphodiesterase 10A pipeline targets constitutes close to nine molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, and Preclinical stages are 3, 1, and 5 respectively.
cAMP and cAMP Inhibited cGMP 3′,5′ Cyclic Phosphodiesterase 10A overview
cAMP and cAMP-inhibited cGMP 3′,5′-cyclic phosphodiesterase 10A is an enzyme which plays a critical role in regulating cAMP and cGMP levels in the striatum. Many cellular responses are regulated by second messengers like cAMP and cGMP. PDE10A eliminate cAMP- and cGMP-mediated intracellular signaling by hydrolyzing the cyclic nucleotide to the corresponding nucleoside 5-prime monophosphate.
For a complete picture of cAMP and cAMP Inhibited cGMP 3′,5′ Cyclic Phosphodiesterase 10A’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
